| 货号 | 78144S |
| 同种亚型 | Rabbit IgG |
| 反应种属 | Human |
| 应用 | WB |
| 目标/特异性 | LILRB1/CD85j (D4L8L) Rabbit mAb recognizes endogenous levels of total LILRB1/CD85J protein. This antibody does not cross-react with LILRB2 protein. |
| 使用方法 | Western Blotting (1:1000) |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | The leukocyte Ig-like receptor subfamily B (LILRB) are type-I transmembrane glycoproteins containing ligand binding extracellular IgG-like domains and immunoreceptor tyrosine-based inhibition motifs (ITIMS) within the cytoplasmic domain, which recruit SHP protein tyrosine phosphatases, leading to transduction of signals that inhibit immune cell activation. Encoded within a region of chromosome 19 known as the leukocyte receptor complex, the LILRB subfamily of inhibitory receptors consists of LILRB1 to LILRB5, also referred to as CD85J, CD85D, CD85A, CD85K, and CD85C, respectively (1). There is mounting evidence that LILRBs function, in part, as a novel class of immune checkpoint receptors and support tumor growth through the transmission of inhibitory signals upon engagement of ligands expressed on tumor cells (2). LILRB1 (CD85j/ILT2/LIR1) is expressed across multiple hematopoietic cell lineages, such as B-cells, NK cells, monocytes, and T-cells (3,4). Like other members of the LILRB subfamily, LILRB1 contains multiple extracellular IgG-like domains and intracellular ITIM motifs (5). Research studies have demonstrated that LILRB1 interacts with multiple HLA class I ligands, such as HLA-G (6). Cross-linking of LILRB1 upon ligand engagement has been shown to activate immunosuppressive signaling cascades, which in B-cells, suppresses their activation and ability to produce antibodies (7). In NK and T cell lineages, research studies have shown that LILRB1 transduces signaling to inhibit cytolytic activity (3). |
| 存放说明 | -20C |
| 计算分子量 | 110 |
| 参考文献 | 1 . Allan, D.S. et al. (2000) Immunobiology 202, 34-41. 2 . Roberti, M.P. et al. (2015) Eur J Immunol 45, 1560-9. 3 . Colonna, M. et al. (1997) J Exp Med 186, 1809-18. 4 . Samaridis, J. and Colonna, M. (1997) Eur J Immunol 27, 660-5. 5 . Borges, L. et al. (1997) J Immunol 159, 5192-6. 6 . Shiroishi, M. et al. (2003) Proc Natl Acad Sci U S A 100, 8856-61. 7 . Naji, A. et al. (2014) J Immunol 192, 1536-46. |
Western blot analysis of extracts from Daudi cells, untreated (-) or treated with PNGase F (+), using LILRB1/CD85j (D4L8L) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower). | |
Western blot analysis of extracts from various cell lines using LILRB1/CD85j (D4L8L) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower). As expected, LILRB1/CD85j protein is not detected in A-431 cells. | |
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with constructs expressing Myc/DDK-tagged full-length human LILRB1 protein (hLILRB1-Myc/DDK; +) or Myc/DDK-tagged full-length human LILRB2 protein (hLILRB2-Myc/DDK; +), using LILRB1/CD85j (D4L8L) Rabbit mAb (upper), DYKDDDDK Tag Antibody #2368 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower). |
